Achillion Pharmaceuticals has received a $15 million milestone payment from Janssen Research & Development, related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

“We are delighted to have reached this milestone … and we look forward to JNJ-4178’s continued clinical advancement,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.